share_log

10-Q: Q1 2024 Earnings Report

10-Q: Q1 2024 Earnings Report

10-Q:2024财年一季报
美股SEC公告 ·  05/08 07:18

Moomoo AI 已提取核心信息

Cingulate Inc., a biopharmaceutical company, reported its financial performance for the quarter ended March 31, 2024. The company experienced a net loss of $2.972 million, a decrease from the $4.004 million loss in the same period the previous year. This reduction in net loss was attributed to a decrease in both research and development expenses, which dropped by 15.1% to $1.807 million, and general and administrative expenses, which fell by 35.1% to $1.117 million. The company's financial position was bolstered by the issuance of common stock under an ATM Agreement and a public offering in February 2024, which provided net proceeds of $3.115 million and $7.5 million, respectively. Cingulate Inc. is focused on developing products for the treatment of ADHD and anxiety, with its lead product candidate, CTx-1301, having completed...Show More
Cingulate Inc., a biopharmaceutical company, reported its financial performance for the quarter ended March 31, 2024. The company experienced a net loss of $2.972 million, a decrease from the $4.004 million loss in the same period the previous year. This reduction in net loss was attributed to a decrease in both research and development expenses, which dropped by 15.1% to $1.807 million, and general and administrative expenses, which fell by 35.1% to $1.117 million. The company's financial position was bolstered by the issuance of common stock under an ATM Agreement and a public offering in February 2024, which provided net proceeds of $3.115 million and $7.5 million, respectively. Cingulate Inc. is focused on developing products for the treatment of ADHD and anxiety, with its lead product candidate, CTx-1301, having completed enrollment in two Phase 3 clinical trials. The company plans to submit a New Drug Application for CTx-1301 in the first half of 2025. Additionally, Cingulate Inc. is developing CTx-1302 and CTx-2103, with plans to initiate clinical plans for CTx-1302 as soon as 2025, pending additional capital resources. The company's future plans include seeking regulatory approval for its product candidates, continuing research and development, and potentially commercializing its products if approval is obtained.
生物制药公司Cingulate Inc.报告了截至2024年3月31日的财务业绩。该公司净亏损297.2万美元,较去年同期的400.4万美元亏损有所减少。减少的净亏损归因于其研发支出和一般行政费用的下降。研发费用下降了15.1%,至180.7万美元,一般行政费用下降了35.1%,至111.7万美元。该公司的财务状况得到了一项ATM协议下的普通股股份发行和2024年2月的公开招股,分别提供了净收益311.5万美元和750万美元。Cingulate Inc.专注于开发用于治疗注意力缺陷/多动障碍和焦虑症的产品,并且旗舰产品候选CTx-1301已经完成了两项III期临床试验的入组。该公司计划在202...展开全部
生物制药公司Cingulate Inc.报告了截至2024年3月31日的财务业绩。该公司净亏损297.2万美元,较去年同期的400.4万美元亏损有所减少。减少的净亏损归因于其研发支出和一般行政费用的下降。研发费用下降了15.1%,至180.7万美元,一般行政费用下降了35.1%,至111.7万美元。该公司的财务状况得到了一项ATM协议下的普通股股份发行和2024年2月的公开招股,分别提供了净收益311.5万美元和750万美元。Cingulate Inc.专注于开发用于治疗注意力缺陷/多动障碍和焦虑症的产品,并且旗舰产品候选CTx-1301已经完成了两项III期临床试验的入组。该公司计划在2025年上半年提交CTx-1301的新药申请。此外,Cingulate Inc.正在开发CTx-1302和CTx-2103,并计划在2025年开始CTx-1302的临床计划,前提是获得额外的资本资源。该公司未来的计划包括寻求产品候选的监管批准,继续开展研究和开发,并在获得批准后可能将其产品商业化。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息